|
⚲
|
| Keyboard |
| North Tide Capital LLC
✚
|
|
|---|---|
| CRD # | 157585 |
| SEC # | 801-73783 |
| CIK # | 0001557543 |
| AUM | |
| Employees | 8 (100% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-449-3120 |
| Address | 500 Boylston Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2017) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION Management Fee and Performance Allocation North Tide is compensated by Main Fund Investors in the form of a monthly management fee (the “Management Fee”) paid by the Master Fund. The Management Fee will be payable in arrears (regardless of a client’s profits) and will be deducted in determining the net profit or net loss of the U.S. Fund and the Offshore Fund. The Management Fee is calculated based on the balance in each Main Fund Investor’s capital account or the net asset value of each Main Fund Investor’s series of shares, as applicable and equals 0.125% per month (approximately 1.5% annualized), at the end of each month (computed prior to the payment or accrual of any Performance Allocation). The Management Fee is prorated for partial months. In connection with the investment management services North Tide provides, it will bear all of its own normal and recurring operating expenses and overhead costs, except that research and research-related expenses may be paid for through the permitted use of “soft dollars” (as described in Item 12 - Brokerage Practices). The Management Fee may exceed the expenses borne by North Tide on behalf of the Main Funds. Generally at the end of each fiscal year, the General Partners will have reallocated to their capital accounts in the Master Funds (after reduction for the Management Fee and other expenses and fees incurred by the U.S. Funds and the Offshore Funds) a Performance Allocation equal to 20% of the excess net profits over net losses attributable to each Fund Investor’s capital account or series of shares (and reflected in corresponding sub-accounts kept with respect to each such Fund Investor at the Master Funds level) for such fiscal year, subject to a customary high-watermark described below. In the event a Fund Investor is permitted or required to withdraw or redeem completely or partially from the U.S. Funds or Offshore Funds other than at the end of the fiscal year, the Performance Allocation made at the Master Funds level with respect to such Fund Investor for such year will be determined with respect to the portion being withdrawn or redeemed through the applicable withdrawal date. A memorandum loss recovery account (a “Loss Recovery Account”), sometimes called a “high- watermark”, will be maintained with respect to each Fund Investor and will be increased by the aggregate net losses, if any, allocated to such Fund Investor for such year and reduced (but not below zero) by any net profits allocated to such Fund Investor for such year (before any Performance Allocation). The General Partners (as applicable) will not be allocated any Performance Allocation with respect to a Fund Investor until such Fund Investor has recovered any net losses allocated to its Loss Recovery Account. The loss amount allocated to the Loss Recovery Account will be decreased pro rata to account for any withdrawals or redemptions made prior to the end of a fiscal year. The Management Fee and Performance Allocation may, in the sole discretion of North Tide or the General Partners (as applicable) be waived, reduced, or rebated with respect to certain Fund Investors, including affiliates of the General Partners or North Tide. North Tide (or an affiliate) deducts applicable fees from Fund Investor assets invested in the Funds. Fund Investors do not have the ability to choose to be billed directly for fees incurred. North Tide also receives from the Account an asset based quarterly management fee and an annual performance based fee, subject to a high-watermark similar to that described above, in the amounts set forth in the agreement between North Tide and the Account investor. Expenses In addition to fees payable to North Tide, the Funds (and therefore Fund Investors) may pay a variety of expenses related to each Fund’s investments and operations, including, without limitation, brokerage and other transaction costs, clearing and settlement charges, trade break fees, consulting expenses, research and due diligence expenses (including research related travel expenses), legal fees and other expenses in connection with conducting due diligence and negotiating the terms of certain investments, custodial fees, initial and variation margin, interest and commitment fees on debit balances or borrowings, stock borrowing fees and proxy solicitation expenses, legal expenses, audit and tax preparation expenses, accounting fees, costs of the administration of the Funds (including, but not limited to, fees and expenses of an administrator and third party valuation services), the Management Fee, regulatory costs and expenses (including filing and licensing fees), organizational expenses, premiums for liability insurance, fees for risk management services, indemnification expenses, entity-level taxes, issue or transfer taxes, costs of reporting to investors, costs of litigation or investigation involving Fund activities, any extraordinary expenses, and other similar expenses related to the Funds. A portion of the Funds’ expenses may be shared with other investment entities or accounts managed by North Tide, the General Partners or their affiliates on an equitable basis. Neither North Tide nor its supervised persons accept compensation, including sales charges or service fees, from any person for the sale of securities or other investment products, including interests in the Funds. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2017) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS As previously described in Item 4, North Tide’s clients consist of the Funds and the Account. Investors in the Funds and the Account consist of institutional investors and other sophisticated investors. The minimum investment in the Funds is $1,000,000, which may be reduced by the General Partners of the U.S. Funds or Board of Directors of the Offshore Funds, as applicable. Interests in the U.S. Funds may only be purchased by investors that are “accredited investors,” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), and “qualified purchasers,” as defined in Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended (the “1940 Act”). U.S. investors in the Offshore Funds must also be “accredited investors” and “qualified purchasers.” Shares in the Offshore Funds are typically offered to eligible investors that are not U.S. Persons or U.S. tax-exempt entities. The Account was established for a sophisticated institutional investor and involves a significant minimum investment. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| McKesson Corp | 76.8 | ||
| Gilead Sciences Inc | 40.5 | ||
| Perrigo Co Ltd | 25.4 | ||
| Tenet Healthcare Corp | 25.2 | ||
| CVS Caremark Corp | 20.3 | ||
| Pacific Biosciences of California Inc | 5.2 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Slack Tide-SPV 1 LLC | 2026-06-17 | ||
| HF | NTC Special Opportunities I Master LP | [2016-11-16] | 20.6 M | 84.6 M |
| Filed 2017-07-27 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | North Tide Capital Master LP | [2012-02-14] | 25.1 M | 1,261.8 M |
| Filed 2017-10-30 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 1.6 |
| By Discretionary | ||
| Discretionary | 7 | 1.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 1.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 1.6 | |
| Total | 7 | 1.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Ronan Guilfoyle | Director | 358 | 108 | |
| Jennifer Collins | Director | 232 | 47 | |
| Kevin Phillip | Director | 193 | 39 | |
| Evan Burtton | Director | 83 | 34 | |
| Conan Laughlin | Director, Executive Officer | 4 | 2 | |
| North Tide Capital LLC | Promoter | 3 | 2 | |
| North Tide Capital GP II LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001557543] | |
| 3 | [0001557543] | |
| 4 | [0001557543] | |
| SC 13D | [0001557543] | |
| SC 13G | [0001557543] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Vivus Inc VVUS
Common Stock
|
2017-03-10 | Sell | 77,000 | $1.17 | 90,090 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-09 | Sell | 237,100 | $1.20 | 284,520 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-09 | Sell | 50,000 | $1.25 | 62,500 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-09 | Sell | 435,300 | $1.21 | 526,713 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-08 | Sell | 350,000 | $1.05 | 367,500 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-07 | Sell | 105,100 | $1.07 | 112,457 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-07 | Sell | 40,000 | $1.08 | 43,200 |
|
Syneron Medical Ltd ELOS
Common Stock
|
2017-03-07 | Sell | 34,000 | $10.30 | 350,200 |
|
Syneron Medical Ltd ELOS
Common Stock
|
2017-03-07 | Sell | 81,500 | $10.28 | 837,820 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-06 | Sell | 10,000 | $1.10 | 11,000 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-06 | Sell | 4,800 | $1.10 | 5,280 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-03 | Sell | 31,200 | $1.11 | 34,632 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-03 | Sell | 1,700 | $1.11 | 1,887 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-02 | Sell | 20,000 | $1.13 | 22,600 |
|
Tivity Health Inc TVTY
Common Stock, $0.001 Par Value
|
2017-03-01 | Sell | 250,000 | $28.30 | 7,075,000 |
|
Tivity Health Inc TVTY
Common Stock, $0.001 Par Value
|
2017-03-01 | Sell | 1,750,000 | $28.30 | 49,525,000 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-01 | Sell | 72,600 | $1.14 | 82,764 |
|
Vivus Inc VVUS
Common Stock
|
2017-03-01 | Sell | 42,000 | $1.13 | 47,460 |
|
Vivus Inc VVUS
Common Stock
|
2017-02-28 | Sell | 25,500 | $1.12 | 28,560 |
|
Vivus Inc VVUS
Common Stock
|
2017-02-27 | Sell | 107,000 | $1.13 | 120,910 |
| showing 20 of 178 most recent transactions | |||||